Pinnacle Associates’s CorMedix CRMD Stock Holding History

Pinnacle Associates’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,000	Closed	-$37.6K	–	845
2024 Q3	$37.6K	Hold	10,000	–	–	﹤0.01%	794
2024 Q2	$43.3K	Hold	10,000	–	–	﹤0.01%	806
2024 Q1	$42.4K	Hold	10,000	–	–	﹤0.01%	826
2023 Q4	$37.6K	Hold	10,000	–	–	﹤0.01%	809
2023 Q3	$37K	Hold	10,000	–	–	﹤0.01%	805
2023 Q2	$39.6K	Hold	10,000	–	–	﹤0.01%	808
2023 Q1	$41.4K	Hold	10,000	–	–	﹤0.01%	763
2022 Q4	$42.2K	Hold	10,000	–	–	﹤0.01%	750
2022 Q3	$28K	Buy	+10,000	New	+$41.6K	﹤0.01%	732

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $935M AUM 298.58% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pinnacle Associates's CRMD Position: Q4 2024 in Review

Pinnacle Associates sold out of CorMedix (CRMD) in Q4 2024, closing a stake of 10,000 shares — an estimated $37.6K sold.

Pinnacle Associates first reported a position in CRMD in Q3 2022 and held it in 9 quarters. The position peaked at $43.3K in Q2 2024. 129 funds tracked by Wall St. Rank hold CRMD as of Q4 2024.

Pinnacle Associates reported no remaining CorMedix position as of Q4 2024 after selling out during the quarter.
Pinnacle Associates sold 10,000 CorMedix shares in Q4 2024, an estimated $37.6K.
Pinnacle Associates first reported a position in CorMedix in Q3 2022 and held it in 9 quarters.
Pinnacle Associates's CorMedix position peaked at $43.3K in Q2 2024.
129 funds tracked by Wall St. Rank held CorMedix as of Q4 2024.

Based on Pinnacle Associates's 13F filing for Q4 2024, filed 14 Feb 2025.